Huai-Rong Luo1, Andrea Gaedigk, Vasileios Aloumanis, Yu-Jui Yvonne Wan. 1. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Mail Stop 1018, Breidenthal Building, 3901 Rainbow Blvd., Kansas City, KS 66160-7417, USA.
Abstract
OBJECTIVES: To extend the genotyping analysis of the CYP2D6 gene and further explain variability of CYP2D6 activity in Mexican Americans by genetic factors. METHODS: CYP2D6 gene sequence variations associated with *6, *7, *8, *9, *11, *14, *29, *41, *45, and *46 alleles as well as the 2988G>A SNP were examined in 264 Mexican Americans; 236 had previously been phenotyped with dextromethorphan. All subjects were previously genotyped for CYP2D6*2, *3, *4, *5, *10, *17, and the presence of a gene duplication. Associations between genotype and CYP2D6 activity were determined. RESULTS: Mexican Americans revealed a high frequency of functional alleles (CYP2D6*1 and *2; 73.1%), followed by CYP2D6*4 (non-functional, 10.0%) and the reduced-function allele *41 (9.5%). The frequencies of CYP2D6*5, *6, *9, *10, duplication, and 2988A were 1.7%, 0.4%, 1.1%, 2.8%, 0.8%, and 5.7%, respectively. CYP2D6*3, *17, and *29 were found only in one individual (CYP2D6*2/*3, *1/*17, and *4/*29), while CYP2D6*7, *8, *11, *14, *45, and *46 were absent in this study population. Decreased CYP2D6 activity was more accurately predicted by the presence *41[-1584C] compared to *41[2988A]. One genotype/phenotype discordant subject was resolved by the presence of a CYP2D6*6 allele (*4/*6), while two other cases remained discordant (*41/*41 and *1/*1). CONCLUSIONS: The CYP2D6*4, *5, and *6 null alleles along the reduced function alleles *9, *10, and *41 are the major cause for diminished dextromethorphan oxidative capacity in Mexican Americans. These findings may have implications for the safety and efficacy of CYP2D6 substrates taken by Mexican Americans.
OBJECTIVES: To extend the genotyping analysis of the CYP2D6 gene and further explain variability of CYP2D6 activity in Mexican Americans by genetic factors. METHODS:CYP2D6 gene sequence variations associated with *6, *7, *8, *9, *11, *14, *29, *41, *45, and *46 alleles as well as the 2988G>A SNP were examined in 264 Mexican Americans; 236 had previously been phenotyped with dextromethorphan. All subjects were previously genotyped for CYP2D6*2, *3, *4, *5, *10, *17, and the presence of a gene duplication. Associations between genotype and CYP2D6 activity were determined. RESULTS: Mexican Americans revealed a high frequency of functional alleles (CYP2D6*1 and *2; 73.1%), followed by CYP2D6*4 (non-functional, 10.0%) and the reduced-function allele *41 (9.5%). The frequencies of CYP2D6*5, *6, *9, *10, duplication, and 2988A were 1.7%, 0.4%, 1.1%, 2.8%, 0.8%, and 5.7%, respectively. CYP2D6*3, *17, and *29 were found only in one individual (CYP2D6*2/*3, *1/*17, and *4/*29), while CYP2D6*7, *8, *11, *14, *45, and *46 were absent in this study population. Decreased CYP2D6 activity was more accurately predicted by the presence *41[-1584C] compared to *41[2988A]. One genotype/phenotype discordant subject was resolved by the presence of a CYP2D6*6 allele (*4/*6), while two other cases remained discordant (*41/*41 and *1/*1). CONCLUSIONS: The CYP2D6*4, *5, and *6 null alleles along the reduced function alleles *9, *10, and *41 are the major cause for diminished dextromethorphan oxidative capacity in Mexican Americans. These findings may have implications for the safety and efficacy of CYP2D6 substrates taken by Mexican Americans.
Authors: Katherine D Furman; David R Grimm; Toby Mueller; Rhonda R Holley-Shanks; Richard J Bertz; Laura A Williams; Brian B Spear; David A Katz Journal: Pharmacogenetics Date: 2004-05
Authors: Connie J Mulligan; Robert W Robin; Michael V Osier; Nyamkhishig Sambuughin; Lev G Goldfarb; Rick A Kittles; Diane Hesselbrock; David Goldman; Jeffrey C Long Journal: Hum Genet Date: 2003-07-12 Impact factor: 4.132
Authors: G Vargas-Alarcón; A Garcia; S Bahena; H Melin-Aldana; F Andrade; G Ibañez-de-Kasep; J Alcocer-Varela; D Alarcón-Segovia; J Granados Journal: Ann Rheum Dis Date: 1994-11 Impact factor: 19.103
Authors: R Saxena; G L Shaw; M V Relling; J N Frame; D T Moir; W E Evans; N Caporaso; B Weiffenbach Journal: Hum Mol Genet Date: 1994-06 Impact factor: 6.150
Authors: Cynthia A Prows; Todd G Nick; Shannon N Saldaña; Sanjeev Pathak; Chunyan Liu; Kejian Zhang; Zachary S Daniels; Alexander A Vinks; Tracy A Glauser Journal: J Child Adolesc Psychopharmacol Date: 2009-08 Impact factor: 2.576
Authors: M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena Journal: Pharmacogenomics J Date: 2016-06-07 Impact factor: 3.550
Authors: Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos Journal: Genet Test Mol Biomarkers Date: 2012-08-22
Authors: Ha Hai Nguyen; Thuong Thi Huyen Ma; Nhung Phuong Vu; Quynh Thi Nhu Bach; Thang Hong Vu; Ton Dang Nguyen; Hai Van Nong Journal: Medicine (Baltimore) Date: 2019-05 Impact factor: 1.817